Newsroom
Sorted by: Latest
-
5 Stones intelligence (5Si)® Launches The Art of Intelligence™ Thought Leadership Platform
MIAMI--(BUSINESS WIRE)--5Si® launches The Art of Intelligence™ cinematic thought leadership platform exploring modern intelligence, risk, and high-stakes decision-making....
-
Render Networks Advances ClearWay with Field Quality Agent, Bringing Real-Time Validation to Critical Infrastructure Execution
DENVER--(BUSINESS WIRE)--Render Networks Advances ClearWay with Field Quality Agent, Bringing Real-Time Validation to Critical Infrastructure Execution...
-
Reggaetón Pioneer El General Reignites World Cup Spirit With “Vamos a Ganar” in Partnership with Intercept Music
MIAMI--(BUSINESS WIRE)--Intercept Music partners with reggaetón pioneer El General for the worldwide release of the revitalized anthem “Vamos a Ganar.”...
-
AMC Theatres® Expands Feature Fare Menu Nationwide With New Craveable Favorites Including Street Corn Poppers, Hot Honey Sausage Pizza, and Popcorn Chicken
LEAWOOD, Kan.--(BUSINESS WIRE)--AMC Theatres® (NYSE: AMC), the largest theatrical exhibitor in the United States and the world, is introducing an expanded lineup of new menu items at AMC Feature Fare locations nationwide, giving moviegoers even more ways to enjoy bold flavors and elevated snacks alongside this summer’s biggest movies. Available at more than 400 AMC locations in the United States, AMC Feature Fare continues to evolve beyond traditional movie theatre concessions with a growing li...
-
lululemon Highlights Strength of its Refreshed Board, with the Right Expertise to Drive the Company’s Next Phase of Growth and Enhanced Shareholder Value
VANCOUVER, British Columbia--(BUSINESS WIRE)--lululemon athletica inc. (NASDAQ:LULU) today filed definitive proxy materials with the Securities and Exchange Commission in connection with the company's upcoming Annual Meeting of Shareholders (the “Annual Meeting”) to be held on June 25, 2026. Shareholders of record as of April 30, 2026 will be entitled to vote at the meeting. The definitive proxy statement and other important information related to the Annual Meeting can be found at voteforlulul...
-
Pathward’s Matt Dekutoski Among ABF Journal’s 2026 Icons
SIOUX FALLS, S.D.--(BUSINESS WIRE)--Matt Dekutoski of Pathward has been honored as an Icon by ABF Journal in its 2026 Leaders and Legends issue....
-
RAMP Stock Alert: Halper Sadeh LLC is Investigating Whether LiveRamp Holdings, Inc. is Obtaining a Fair Price for its Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of LiveRamp Holdings, Inc. (NYSE: RAMP) to Publicis Groupe for $38.50 per share. Halper Sadeh encourages LiveRamp shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether LiveRamp and its board of directors violated the f...
-
Computershare Trustees (Jersey) Limited UK Regulatory Announcement: Form 8.3
LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Computershare Trustees (Jersey) Limited as trustee of the Schroders Employee Benefit Trust (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. Fo...
-
Turn Therapeutics Appoints Physician-Scientist and Former FDA Commissioner, Dr. Stephen M. Hahn, as Executive Clinical and Regulatory Lead
WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, localized therapies for inflammatory skin diseases, today announced the appointment of Stephen M. Hahn, M.D., former Commissioner of the U.S. Food and Drug Administration (FDA), to oversee the clinical and regulatory strategy for GX-03, the Company’s investigational topical therapy currently in a Phase 2 clinical trial for moderate-to-severe atopic dermat...
-
Ameresco's Kūpono Project Named Winner in 2026 Environment+Energy Leader Awards
FRAMINGHAM, Mass.--(BUSINESS WIRE)--Ameresco's Kūpono Project Named Winner in 2026 Environment+Energy Leader Awards...